Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed

In their CMAJ commentary, Cheng and colleagues highlight the importance of evaluating potential COVID-19 therapies systematically within randomized controlled trials (RCTs).[1][1] In addition to cost, another limiting factor for clinical trials is speed of enrolment. For researchers to derive robust